Amylyx Pharmaceuticals (AMLX) Cash from Financing Activities (2021 - 2026)

Amylyx Pharmaceuticals' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 95.1% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $194.6 million (up 195.37% YoY), while the FY2025 annual figure was $257.0 million, up 73758.91% from the prior year.
• Cash from Financing Activities was $3.2 million for Q1 2026 at Amylyx Pharmaceuticals, up from -$208000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $232.2 million in Q4 2022 to a low of -$828000.0 in Q2 2022.
• Historically, Cash from Financing Activities has averaged $43.5 million across 5 years, with a median of $559500.0 in 2023.
• Biggest YoY gain for Cash from Financing Activities was 239407.5% in 2025; the steepest drop was 289.09% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $232.2 million in 2022, then tumbled by 99.9% to $230000.0 in 2023, then sank by 52.17% to $110000.0 in 2024, then sank by 289.09% to -$208000.0 in 2025, then soared by 1646.63% to $3.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.2 million (Q1 2026), -$208000.0 (Q4 2025), and $191.6 million (Q3 2025), per Business Quant data.